Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
DSM Biologics to Produce Antibody for MorphoSys
10:48 AM MDT | August 25, 2008 | Deepti Ramesh
DSM Biologics, a unit of DSM, says it has signed a biopharmaceutical manufacturing agreement with biotech firm MorphoSys (Martinsried, Germany). The deal calls for DSM to develop and manufacture MOR202, a fully human antibody for the treatment of multiple myeloma, at its facility in Groningen, Netherlands. Financial terms were not disclosed. Sproll: Continuing the PER.C6 platform. DSM will use the PER.C6 technology platform of biotech firm Crucell (Leiden, Netherlands). PER.C6 has been developed for large-scale manufacturing of biopharma products including...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee